

Financial Highlights

(Billions of yen)

Consolidated Management Index	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	1H 2016 <unaudited>	Estimate 1H 2017	Estimate 2017
Net sales	(Billions of yen) 1,427.4	1,195.5	280.3	280.2	587.7	605.0	1,260.0
	YoY	-16.2%		-0.0%		3.0%	5.4%
Cost of sales	(Billions of yen) 452.5	406.3	95.5	95.5	197.4	205.0	435.0
	YoY	-10.2%		-0.1%		3.9%	7.1%
Selling, general and administrative expenses	(Billions of yen) 636.4	535.9	119.7	122.0	248.1	265.0	540.0
	YoY	-15.8%		1.9%		6.8%	0.8%
R&D expenses	(Billions of yen) 202.7	168.8	36.4	36.7	71.2	85.0	180.0
	YoY	-16.7%		0.6%		19.5%	6.6%
Share of profit of associates accounted for using equity method	(Billions of yen) 12.4	16.0	3.8	4.4	9.2	8.0	15.0
	YoY	29.1%		14.2%		-13.0%	-6.1%
Operating profit	(Billions of yen) 148.9	101.1	34.0	30.2	82.3	58.0	120.0
	YoY	-32.1%		-11.2%		-29.5%	18.7%
Profit attributable to owners of parent	(Billions of yen) 102.0	92.6	21.9	21.0	49.6	42.0	85.0
	YoY	-9.2%		-3.9%		-15.3%	-8.2%
Overseas net sales	(Billions of yen) 804.9	571.5	142.0	141.2	290.8	294.5	611.0
	% of net sales	56.4%	50.7%	50.4%	49.5%	48.7%	48.5%

(Yen)

Exchange rate (Yen)	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Estimate 2017
US\$	121.10	108.77	115.35	113.60	115.00
Euro	134.30	120.25	127.14	121.05	120.00

(Billions of yen)

Selling, general and administrative expenses	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	1H 2016 <unaudited>	Estimate 1H 2017	Estimate 2017
Selling, general and administrative expenses	636.4	535.9	119.7	122.0	248.1	265.0	540.0
(% of net sales)	44.6%	44.8%	42.7%	43.6%	42.2%	43.8%	42.9%
Personnel expenses	172.9	167.8	43.1	41.8			
Depreciation and amortization expenses	33.8	32.8	7.8	8.2			
Advertising expenses	33.3	41.5	7.7	9.9			
Promotion expenses	176.8	97.8	21.1	21.7			
Impairment loss	18.9	16.3	0.0	0.0			
R&D expenses	202.7	168.8	36.4	36.7	71.2	85.0	180.0
(% of net sales)	14.2%	14.1%	13.0%	13.1%	12.1%	14.0%	14.3%
R&D expenses of pharmaceutical business	193.0	159.4	34.3	34.5	66.5	80.0	170.0

(Billions of yen)

Capital expenditures	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	1H 2016 <unaudited>	Estimate 1H 2017	Estimate 2017
Capital expenditures	526.5	75.5	18.6	47.8	32.0	30.0	60.0

(Billions of yen)

Depreciation	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	1H 2016 <unaudited>	Estimate 1H 2017	Estimate 2017
Depreciation	59.2	59.6	14.4	15.4	30.0	32.0	65.0

Sales to Customers by Market

(Billions of yen)

Net sales by business segment	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Change
Consolidated sales	1,427.4	1,195.5	280.3	280.2	-0.0%
Pharmaceutical business	973.5	753.0	182.2	180.4	-1.0%
Japan	386.1	387.9	90.3	91.2	1.0%
North America	368.1	218.7	54.4	51.6	-5.2%
Others	219.3	146.4	37.4	37.6	0.4%
Nutraceutical business	306.7	300.9	64.6	65.4	1.3%
Japan	128.7	133.8	24.4	24.4	0.0%
North America	86.4	79.2	18.6	19.6	5.4%
Others	91.6	87.8	21.6	21.4	-0.8%
Consumer products business	38.2	35.2	7.9	7.3	-7.3%
Japan	28.0	26.4	5.5	5.0	-9.1%
North America	9.7	8.3	2.4	2.3	-2.9%
Others	0.5	0.5	0.0	0.0	-20.7%
Other business	108.9	106.5	25.6	27.1	5.9%
Japan	79.7	75.9	18.1	18.5	2.0%
North America	1.9	2.9	0.7	0.7	3.0%
Others	27.4	27.6	6.8	7.9	16.6%
Japan -total	622.5	624.0	138.3	139.0	0.5%
North America - total	466.1	309.2	76.1	74.2	-2.5%
Others - total	338.7	262.3	65.9	67.0	1.6%
Overseas net sales	804.9	571.5	142.0	141.2	-0.6%
Overseas net sales ratio	56.4%	47.8%	50.7%	50.4%	

Net Sales and Operating Income by Geographical and Business Segment

(1) Geographical segment

(Billions of yen)

	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Change
Net sales	1,427.4	1,195.5	280.3	280.2	-0.0%
Japan*	818.6	768.2	170.9	173.4	1.5%
North America*	542.5	363.0	93.0	89.9	-3.3%
Others*	257.7	230.6	59.8	59.4	-0.7%
Eliminations/corporate	-191.5	-166.2	-43.4	-42.5	

*Intersegment sales are included.

(Billions of yen)

	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Change
Operating income	148.9	101.1	34.0	30.2	-11.2%
Japan	85.2	83.1	20.6	17.6	-14.7%
North America	2.1	2.2	8.4	4.5	-46.0%
Others	20.8	12.2	7.4	9.3	25.2%
Eliminations/corporate	40.7	3.7	-2.4	-1.2	

(2) Business segment

(Billions of yen)

	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Change
Net sales	1,427.4	1,195.5	280.3	280.2	-0.0%
Pharmaceutical business*	973.5	753.0	182.2	180.4	-1.0%
Nutraceutical business*	315.4	311.6	67.1	68.1	1.5%
Consumer products business*	38.5	35.5	8.0	7.4	-7.4%
Other business*	145.2	141.3	33.6	35.5	5.4%
Eliminations/corporate	-45.2	-45.7	-10.6	-11.1	

*Intersegment sales are included.

(Billions of yen)

	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Change
Operating income	148.9	101.1	34.0	30.2	-11.2%
Pharmaceutical business	146.9	92.0	31.2	28.7	-8.2%
Nutraceutical business	34.4	32.5	7.4	6.2	-16.1%
Consumer products business	6.3	5.5	2.5	2.2	-11.1%
Other business	1.0	7.8	2.1	2.7	27.2%
Eliminations/corporate	-39.7	-36.6	-9.2	-9.6	

II-1. Sales of Major Products

[Pharmaceutical business]

(Billions of yen)

Product name	Company	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Change	Estimate 1H 2017	Estimate 2017
Antipsychotic agent ABILIFY	Otsuka Pharmaceutical	347.5	95.4	34.0	17.8	-47.6%	35.5	66.0
US		242.1	27.8	12.7	3.7	-71.0%	6.0	11.5
<US\$ million>		<1,999>	<255>	<110>	<32>	-70.6%	<52>	<100>
Japan		35.6	31.7	7.6	7.1	-7.1%	16.0	30.0
Others		69.7	35.9	13.8	7.1	-48.4%	13.5	24.5
Antipsychotic agent/ Depot injection Abilify Maintena	Otsuka Pharmaceutical	40.4	57.2	13.4	15.6	16.3%	33.5	72.5
US		29.9	37.4	9.0	9.5	5.1%	20.5	44.0
Japan		1.3	4.3	0.8	1.3	73.9%	3.0	7.5
Others		9.2	15.5	3.6	4.8	32.2%	10.0	21.0
Antipsychotic agent REXULTI	Otsuka Pharmaceutical	4.6	29.8	4.4	10.1	132.0%	23.0	48.0
Agent for pseudobulbar affect (PBA) NUDEXTA	Otsuka Pharmaceutical	19.2	23.6	5.6	6.2	10.5%	14.5	31.0
Anti-platelet agent Pletaal/Pletal	Otsuka Pharmaceutical	31.5	23.6	6.2	5.1	-18.3%	10.0	20.0
Japan		23.3	16.2	4.2	3.2	-25.3%	6.5	12.5
Others		8.2	7.4	2.0	1.9	-3.6%	3.5	7.5
Anti-gastritis and anti-gastric ulcer agent Mucosta	Otsuka Pharmaceutical	15.8	12.5	3.5	2.9	-15.7%	5.0	9.0
Japan		11.4	8.2	2.3	1.7	-25.3%	2.5	4.5
Others		4.4	4.3	1.2	1.2	2.9%	2.5	4.5
Anti-metabolite TS-1	Taiho Pharmaceutical	29.3	26.9	6.6	6.0	-9.3%	12.5	21.0
Anti-metabolite UFT	Taiho Pharmaceutical	7.5	6.5	1.4	1.3	-10.8%	3.0	5.5
Reduced folic acid formulation Uzel	Taiho Pharmaceutical	10.5	9.7	2.3	1.6	-28.8%	3.5	7.0
Antineoplastic LONSURF	Taiho Pharmaceutical	9.4	30.1	7.8	8.6	10.9%	16.5	34.0
US		6.0	23.5	6.9	5.9	-15.2%	12.5	26.5
Japan		3.3	3.9	0.8	0.9	15.5%	2.0	4.0
Others		0.1	2.8	0.0	1.8	4028.0%	2.0	3.5
5-HT ₃ receptor antagonist Aloxi	Taiho Pharmaceutical	12.9	14.0	3.2	3.2	0.9%	7.0	14.5
Antineoplastic Abraxane	Taiho Pharmaceutical	20.6	20.7	5.0	4.8	-3.2%	10.0	20.5
Antiepileptic E Keppra	Otsuka Pharmaceutical	23.3	28.5	6.3	7.3	14.9%	15.0	32.5
V ₂ -vasopressin receptor antagonist Samsca/JINARC	Otsuka Pharmaceutical	41.6	48.9	11.4	13.6	19.2%	29.0	60.0
Japan		25.7	30.5	6.9	8.5	22.5%	18.5	39.0
US		11.8	12.1	3.1	3.0	-5.1%	6.5	13.0
Others (including JINARC)		4.0	6.2	1.3	2.1	59.3%	4.0	8.0
Agent for dry eye Mucosta ophthalmic suspension	Otsuka Pharmaceutical	4.5	4.8	1.2	1.2	4.0%	2.5	5.0
Parkinsons' disease, RLS* treatment Neupro Patch	Otsuka Pharmaceutical	8.3	10.7	2.2	2.6	19.1%	6.0	12.5
Anticancer Sprycel (collaboration with BMS)	Otsuka Pharmaceutical	31.2	29.3	6.7	7.4	10.3%	15.5	31.0
Antibiotic Zosyn/Tazocin (bulk supply)	Taiho Pharmaceutical	13.4	8.8	2.6	2.0	-22.4%	2.5	5.5
Diagnostics -total	Otsuka Pharmaceutical	12.2	13.7	4.9	3.8	-22.9%	7.5	13.5
Parenteral nutrition (clinical nutrition) -total	Otsuka Pharmaceutical Factory	106.2	107.4	24.8	25.0	0.6%	53.0	111.0
Japan		88.2	86.7	19.4	19.4	-0.2%	42.5	89.0
Others		18.0	20.7	5.4	5.6	3.4%	10.5	22.0
Pharmaceutical business -total (excluding exports)	Japan	386.1	387.9	90.3	91.2	1.0%	193.0	397.0
Pharmaceutical business -total	Total	973.5	753.0	182.2	180.4	-1.0%	378.0	780.0
Milestone and upfront revenue		66.0	18.5	1.9	1.2	-33.6%	4.0	14.0

*RLS: Restless legs syndrome

【Nutraceutical business】

(10 thousand cases)

Product name	Company	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Change
Pocari Sweat 1 case: 24 bottles, and other (10 thousand cases)	Otsuka Pharmaceutical					
Japan		2,625	2,846	480	469	-2.2%
Overseas		2,608	2,391	471	432	-8.4%
SOYJOY 1 case: 48 bars (10 thousand cases)	Otsuka Pharmaceutical					
Japan		126	136	28	33	16.8%
Overseas		20	19	5	4	-27.8%
Oronamin C 1 case: 50 bottles (10 thousand cases)	Otsuka Pharmaceutical	1,025	993	183	188	2.7%
Calorie Mate 1 case: 4 barsx30, and other (10 thousand cases)	Otsuka Pharmaceutical	381	402	82	81	-0.3%
Tiovita Drink 1 case: 50 bottles (10 thousand cases)	Taiho Pharmaceutical	345	350	62	61	-2.7%
Solmack (10 thousand of bottles)	Taiho Pharmaceutical	1,501	1,525	276	276	-0.1%

* Overseas sales include sales of consolidated subsidiaries only.

【Consumer business】

(10 thousand cases)

Product name	Company	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Change
Bottled Water 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	504	488	112	93	-17.2%
Match 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	527	554	100	86	-14.1%
Other (tea drinks and other) 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	232	240	51	49	-3.1%

【Other business】

(Billions of yen)

Product name	Company	2015	2016	1Q 2016 (Jan-Mar)	1Q 2017 (Jan-Mar)	Change
Functional chemicals	Otsuka Chemical	34.3	34.1	8.9	9.6	7.1%
Fine chemicals	Otsuka Chemical	10.8	10.3	2.2	2.8	27.4%

Otsuka Group - Pipeline Information

(as of Mar 31, 2017)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Central nervous system & Neurology						
<Abilify Maintena*>: Depot injection	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Bipolar I / Depot injection	US	Filed
OPC-34712 <REXULTI* >	brexpiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Major depressive disorder / Oral	EU	Phase III
				Schizophrenia / Oral	JP, EU	Filed
				Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Posttraumatic stress disorder / Oral	US, EU	Phase II
			Schizophrenia/ Depot injection	US	Phase I	
ASC-01	aripiprazole, sertraline	Otsuka Pharmaceutical	Dopamine partial agonist / Selective serotonin reuptake inhibitor	Major depressive disorder / Oral	JP, Asia	Phase III
AVP-923	dextromethorphan, quinidine	Avanir	NMDA receptor antagonist / Sigma-1 receptor agonist	Dyskinesia associated with Parkinson's disease / Oral	US	Phase II
AVP-786	deuterium-modified dextromethorphan, quinidine	Avanir	NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist	Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Residual schizophrenia symptoms / Oral	US	Phase II
				Disinhibition syndrome in neurodegenerative disorders / Oral	US	Phase II
EB-1020	centanafadine	Neurovance	Norepinephrine, dopamine and serotonin reuptake inhibitor	Attention deficit hyperactivity disorder	US	Phase II
TAS-205		Taiho Pharmaceutical	PGD synthase inhibitor	Duchenne muscular dystrophy / Oral	JP	Phase II
Lu AA36143	nalmefene	Lundbeck	Opioid receptor antagonist	alcohol dependence/ Oral	JP	Phase III
Lu AF20513		Lundbeck	β -amyloid vaccine	Alzheimer's demetia / Injection	EU	Phase I

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.
*: Product names used outside Japan.

Otsuka Group - Pipeline Information

(as of Mar 31, 2017)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Oncology						
TAS-102 <LONSURF>	trifluridine, tipiracil	Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral	Asia	Phase III
				Gastric cancer / Oral	JP, US, EU	Phase III
TAS-118	tegafur, gimeracil, oteracil, folinate	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Pancreatic cancer / Oral	JP, Asia	Phase III
				Gastric cancer / Oral	JP, Asia	Phase III
Pro-NETU	fosnetupitant	Helsinn Healthcare	NK ₁ receptor antagonist	Chemotherapy-induced nausea and vomiting / Injection	JP	Phase II
SGI-110	guadecitabine	Astex	Anti-cancer	Ovarian cancer / Injection	US, EU	Phase II
				Acute myeloid leukemia / Injection	US, EU JP, Asia	Phase III
				Myelodysplastic syndrome / Injection	JP, US, EU Asia	Phase III
AT13387		Astex	Anti-cancer (Molecular-targeted drug)	Non-small cell lung cancer / Injection	US, EU	Phase II
AT7519		Astex	Anti-cancer (Molecular-targeted drug)	Multiple myeloma / Injection	US	Phase II
ASTX727		Astex	Anti-cancer	Myelodysplastic syndrome / Oral	US	Phase II
ASTX660		Astex	Anti-cancer (Molecular-targeted drug)	Solid tumors, Lymphomas / Oral	US	Phase I
OPB-111077		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	US, Asia	Phase I
OPB-111001		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	EU	Phase I
TAS-114		Taiho Pharmaceutical	Anti-cancer (Antitumor enhancer)	Non-small cell lung cancer / Oral	JP, US, EU	Phase II
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Prostate cancer / Oral	JP	Phase II
TAS-116		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Gastrointestinal stromal tumor / Oral	JP	Phase II
TAS-117		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-119		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	US, EU	Phase I
TAS-120		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-121		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS3681		Taiho Pharmaceutical	Anti-androgenic agent	Prostate cancer / Oral	US, EU	Phase I
TAS4464		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors Hematological malignancy / Injection	JP, US, EU	Phase I
ET-743	trabectedin	PharmaMar	Anti-cancer	Ovarian cancer / Injection	JP	Phase I
OCV-501		Otsuka Pharmaceutical	WT1 targeted cancer vaccine	Acute myeloid leukemia / Injection	JP, Asia	Phase II
OCV-C02		OncoTherapy Science	Therapeutic cancer vaccine	Colorectal cancer / Injection	JP	Phase I
OPC-12759	rebamipide	Otsuka Pharmaceutical	Oral mucosal protectant / mucosal healing agent	Stomatitis associated with cancer chemoradiotherapy / Solution	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.
 *: Product names used outside Japan.

Otsuka Group - Pipeline Information

(as of Mar 31, 2017)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Cardiovascular & Renal system						
OPC-41061 <Samsca / JINARC>	tolvaptan	Otsuka Pharmaceutical	V ₂ receptor antagonist	Hepatic edema / Oral	Asia	Filed
				Autosomal dominant polycystic kidney disease / Oral	US Asia	Phase III Filed
				Cardiac edema / Oral	Asia	Filed
				Carcinomatous edema / Oral	JP	Phase II
				Volume overload in hemodialysis / Oral	JP	Phase II
Volume overload in peritoneal dialysis / Oral	JP	Phase II				
AKB-6548	vadadustat	Akebia	HIF-prolyl hydroxylase inhibitor	Anemia associated with chronic kidney disease / Oral	US	Phase III
Other areas						
YP-18 <ZOSYN*>	tazobactam, piperacillin	Taiho Pharmaceutical	Antibiotic agent	Complicated skin, Soft tissue infections (including diabetic foot infections) / Injection	JP	Filed
TAS-303		Taiho Pharmaceutical	Selective norepinephrine reuptake inhibitors	Stress urinary incontinence / Oral	JP	Phase II
OPC-67683 <Delyba*>	delamanid	Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant tuberculosis / Oral	US	Phase III
				Multidrug-resistant tuberculosis for pediatrics/ Oral	EU	Phase II
OPC-12759E <Mucosta Ophthalmic Suspension>	rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes / Eye drops MD (Multi dose)	JP	Phase III
OPF-105	Glucose, electrolyte, amino acid, fat and multivitamin	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Peripheral parenteral nutrition solution / Injection	JP	Phase III
OPA-15406		Otsuka Pharmaceutical	PDE4 inhibitor	Atopic dermatitis / Ointment	JP	Phase II
OPS-2071		Otsuka Pharmaceutical	New quinolone based antibacterial agent	Clostridium difficile infection, enteric infection / Oral	JP, Asia	Phase II
Diagnostics						
C13-CAC	calcium (13C)	Otsuka Pharmaceutical	13C-calcium carbonate breath test	Measurement of gastric acidity / In-vivo diagnostic agent	JP	Phase II
ODK-1003/ ODK-1003-CN	WT1 mRNA RT-PCR Assay Kit	Otsuka Pharmaceutical	WT1 mRNA expression in RNA extracted from leukocytes	Diagnosis for acute lymphoblastic leukemia / In-vitro diagnostic agent	JP	Filed
				Diagnosis for Myelodysplastic syndrome / In-vitro diagnostic agent	Asia	Filed

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

* Product names used outside Japan.

Otsuka Group - Pipeline Information

<Changes in Pipeline information Since December 2017>

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status	Change from 4Q FY2016
Central nervous system & Neurology							
OPC-34712 <REXULTI>	brexpiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Schizophrenia / Oral	JP, EU	Filed	Phase III → Filed
				Posttraumatic stress disorder / Oral	US, EU	Phase II	Phase III → Phase II
				Schizophrenia/ Depot injection	US	Phase I	Added
EB-1020	centanafadine	Neurovance	Norepinephrine, dopamine and serotonin reuptake inhibitor	Attention deficit hyperactivity disorder	US	Phase II	Added
Oncology							
SGI-110	guadecitabine	Astex	Anti-cancer	Myelodysplastic syndrome / Injection	JP, US, EU Asia	Phase III	Phase II → III
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Prostate cancer / Oral	JP	Phase II	Solid tumor → Prostate cancer Phase I → Phase II
TAS4464		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors Hematorological malignancy / Injection	JP, US, EU	Phase I	Added

<Discontinuation of project development>

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
OPC-14597 <ABILIFY>	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Agitation associated with dementia of the Alzheimer's type / Oral	JP	Phase III
Reason for discontinuation of project development : The decision to discontinue development was based on R&D strategy.						
<Abilify Maintena*>: Depot injection	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Bipolar I / Depot injection	JP, EU	Phase III
Reason for discontinuation of project development : The decision to discontinue development was based on R&D strategy.						
Lu AE58054	idalopirdine	Lundbeck	Selective 5-HT ₆ receptor antagonist	Alzheimer's disease / Oral	US, EU	Phase III
Reason for discontinuation of project development : The decision to discontinue development was based on Phase III results.						
<SATIVEX>	nabiximols	GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain / Oral spray	US	Phase III
Reason for discontinuation of project development : The decision to discontinue development was based on Phase III results.						
SGI-110	guadecitabine	Astex	Anti-cancer	Hepatocellular carcinoma / Injection	US, EU	Phase II
Reason for discontinuation of project development : The decision to discontinue development was based on Phase II results.						

*: Product names used outside Japan.